MedTrace Logo

Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection

NCT05419674 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 393

Last updated 2023-02-16

No results posted yet for this study

Summary

This study aims to evaluate the efficacy of dual therapy compared with bismuth-containing quadruple therapy as first-line treatment for Helicobacter Pylori eradication, as well as the safety and economic benefits.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Vonoprazan

Potassium-competitive acid blocker

DRUG

Rabeprazole

Proton pump inhibitor

DRUG

Amoxicillin

Antibiotic for H. pylori eradication

DRUG

Clarithromycin

Antibiotic for H. pylori eradication

DRUG

Colloidal bismuth pectin

Gastric mucosal protective drug with anti-H. pylori effect

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-08-01
Completion
2023-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05419674 on ClinicalTrials.gov